To the full analysis
Biogen stock: growth
BIIBBiogen reported $9.81B in revenue for fiscal 2025, up 1.4% on the prior year, down 6.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.1%
per year from 2006 to 2025, per share 11.9%
Earnings (Annual rate)
9.8%
per year from 2006 to 2025, per share 14.8%
Free cash flow (Annual rate)
6.3%
per year from 2006 to 2025, per share 11.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −6.1% | −0.9% | 7.1% |
| Revenue per share | −4.4% | 3.7% | 11.9% |
| Earnings | −20.2% | −9.6% | 9.8% |
| Earnings per share | −18.7% | −5.4% | 14.8% |
| Free cash flow | −11.6% | −4.0% | 6.3% |
| Free cash flow per share | −10.0% | 0.5% | 11.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $2.68B | $217.51M | $642.96M |
| 2007 | $3.17B | $638.17M | $736.53M |
| 2008 | $4.1B | $783.17M | $1.29B |
| 2009 | $4.38B | $970.13M | $909.25M |
| 2010 | $4.72B | $1.01B | $1.45B |
| 2011 | $5.05B | $1.23B | $1.48B |
| 2012 | $5.51B | $1.38B | $1.63B |
| 2013 | $6.93B | $1.86B | −$1.16B |
| 2014 | $9.7B | $2.93B | $2.63B |
| 2015 | $10.76B | $3.55B | $3.07B |
| 2016 | $11.45B | $3.7B | $3.86B |
| 2017 | $12.27B | $2.54B | $3.68B |
| 2018 | $13.45B | $4.43B | $5.3B |
| 2019 | $14.38B | $5.89B | $6.56B |
| 2020 | $13.44B | $4B | $3.81B |
| 2021 | $10.98B | $1.56B | $3.38B |
| 2022 | $10.17B | $3.05B | $1.14B |
| 2023 | $9.84B | $1.16B | $1.24B |
| 2024 | $9.68B | $1.63B | $2.52B |
| 2025 | $9.81B | $1.29B | $2.05B |
Revenue by segment
How Biogen Inc. makes its money and how that has shifted. Names are as the company reports them.
- MS Product Revenues$4.0B41%
- TYSABRI product$1.7B17%
- Spinraza$1.5B16%
- Fumarate$1.4B15%
- Interferon$945.6M10%
- Other$187.4M2%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| MS Product Revenues | $4.04B | 41.2% |
| TYSABRI product | $1.67B | 17% |
| Spinraza | $1.55B | 15.8% |
| Fumarate | $1.43B | 14.5% |
| Interferon | $945.6M | 9.6% |
| Other | $187.4M | 1.9% |
| Total revenue | $9.81B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jun 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.